Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Howard Marks Discloses 6.8% of Contango Oil & Gas After Its Merger With Crimson

Howard Marks‘ Oaktree Capital Management now holds around 1.3 million shares of Contango Oil & Gas Company (NYSEMKT:MCF), a new filing with the SEC revealed. The position held by Oaktree represents 6.8% of the company. At the same time, Oaktree’s managing director, B. James Ford was appointed to the Board of Directors of Contango. The position was disclosed on the back of the merger between Contango and Crimson Exploration Inc. (NASDAQ:CXPO).


In a second filing, several of Oaktree’s affiliates disclosed closing out their positions in Crimson. Oaktree Capital Management in its latest 13F disclosed holding 15.5 million shares of the company.

Disclosure: none

Recommended Reading:

4 Hedge Funds Heavily Invested in Apple’s Fate

Longbow Securities Makes a Couple Rare Moves in NQ Mobile

Tiger Global Ups Position in Carter’s to 10.4%

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.